1. Shepherd J. The role of the exogenous pathway in hypercholesterolemia. Eur Heart J Suppl 2001;3(suppl E):E2-E5.

2. Turley SD. Dietary cholesterol and the mechanisms of cholesterol absorption. Eur Heart J Suppl 1999;1(suppl S):S29-S35.

3. Bays H. Ezetimibe. Expert Opin Investig Drugs 2002;11:1587-1604.

4. Summary of Product Characteristics, Ezetrol. MSP Singapore Company, LLC, 2002.

5. Davidson MH, McGarry T, Bettis R et al on behalf of the Ezetimibe Study Group. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-2134.

6. Ballantyne CM, Houri J, Notarbartolo A et al for the Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003;107:2409-2415.

7. Kerzner B, Corbelli J, Sharp S et al for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with lovastatin in patients with primary hypercholesterolemia. Am J Cardiol 2003;91:418-424.

8. Melani L, Mills R, Hassman D et al for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia:
A prospective, randomized, double-blind trial. Eur Heart J 2003;24:717-728.

9. van Heek M, Farley C, Compton DS et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663.  Br J Pharmacol 2000;129:1748-1754.

10. Data from registration file, MSD and Schering-Plough.